Objective: We retrospectively evaluated the antitumor effect, survival and toxicities of hepatic arterial infusion therapy using a fine powder formulation of cisplatin (cisplatin powder) in hepatocellular carcinoma patients with portal vein tumor thrombosis. Methods: Twenty-four patients classified as Child -Pugh class A or B underwent a single session of hepatic arterial infusion therapy using cisplatin powder. The treatment was repeated every 4 -6 weeks in patients with no evidence of tumor progression or unacceptable toxicity. The treatment response was evaluated using contrast-enhanced computed tomography performed 1 month after each treatment. The survival rate was evaluated using the Kaplan -Meier method, and predictors of a better outcome were identified using univariate analysis. Results: The mean follow-up period was 11.2 months (range, 1.3 -44.2 months). A total of 57 sessions of intra-arterial infusion (1 -6 sessions per patient; mean, 2.4 sessions) with cisplatin powder were performed. A complete response and a partial response were obtained in one and four patients, respectively (objective response rate ¼ 20.8%). The median survival time for all the patients was 7.0 months; the median survival times for the 5 responders and 19 non-responders were 37.3 and 5.6 months, respectively. The 1-and 2-year survival rates were 38% and 16%, respectively. Significant prognostic factors related to survival were the therapeutic effect, patient age and serum alanine aminotransferase level. Severe adverse reactions resulting in treatment discontinuation were not observed, and all the toxicities were successfully managed using conservative treatment. Conclusions: Hepatic arterial infusion therapy with a fine powder formulation of cisplatin was safe, well-tolerated and might help to prolong the life span of advanced hepatocellular carcinoma patients with portal vein tumor thrombosis.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a frequent cause of cancer death worldwide (1) . Despite progress in several modalities of treatment including surgical resection (2) , liver transplantation (3), transarterial chemoembolization (TACE) (4), transarterial chemotherapy in which an anticancer agent was administered in combination with lipiodol (5), percutaneous ethanol injection (PEI) (6) , microwave coagulation therapy (6,7) and radiofreqency ablation (RFA) (8) , many HCC patients have poor liver function as a result of cirrhosis, and HCC has a high recurrence rate and a poor prognosis (9, 10) . HCC is also associated with a high risk of portal vein invasion, and the presence of portal vein tumor thrombosis (PVTT) is correlated with an extremely poor prognosis. HCC patients with PVTT have been treated using surgical resection (11) , systemic chemotherapy (12) , TACE (13) and hepatic arterial infusion (HAI) chemotherapy in which an anticancer agent is repetitively infused without lipiodol or embolic material (14) . Because of the potential risk of hepatic insufficiency, however, surgical resection and TACE are only feasible in patients with well-preserved hepatic function whose PVTTs are localized in a peripheral portal branch. Unsatisfactory results have been reported for systemic chemotherapy for the treatment of HCC patients with PVTT (12, 15) . HAI chemotherapy, which increases the local concentrations of antitumor agents and reduces systemic side effects, has been used as a palliative treatment with some reported efficacy (14, 16, 17) . However, the number of candidates for most treatment modalities is extremely limited (10, 18) .
Cisplatin is widely used for the treatment of a variety of malignancies, including HCC. Cisplatin has been administered for transarterial chemotherapy in combination with lipiodol (19 -21) and/or embolic material (22, 23) with favorable results for HCC patients. The efficacy of HAI therapy with cisplatin alone, however, has been limited (16, 24) . In 2004, a fine powder formulation of cisplatin (cisplatin powder) (IA call w ; Nippon Kayaku, Tokyo, Japan) was developed for use in the treatment of HCC via a transarterial approach without lipiodol or embolic material. Cisplatin powder can be administered about three times higher concentration than that of conventional cisplatin in a single session of HAI therapy without the need of an implanted port and catheter. HAI therapy with cisplatin powder has been demonstrated as being potentially useful for the treatment of advanced HCC (25) . However, no data assessing the efficacy of cisplatin powder as a means of treating HCC patients with PVTT are available. The aim of this study was to assess the antitumor effect, survival and toxicities of HAI therapy with cisplatin powder in HCC patients with PVTT. with PVTT were enrolled in this retrospective study. Five of these patients were diagnosed as having PVTT before being treated, and the other 19 patients were diagnosed as having PVTT while being treated for HCC. The initial treatment of these 19 patients consisted of hepatic resection in 3 patients, local ablation therapy (RFA or PEI) in 6 patients and TACE with epirubicin in 10 patients. Local recurrence or new nodules developed in 13 patients before the diagnosis of PVTT, and 4 of these patients were treated using local ablation therapy, 6 were treated using TACE with epirubicin and 3 were treated using both modalities. The interval between the initial therapy and the diagnosis of PVTT was 1.6 -73.4 months (mean, 29.5 months). The treatment enrollment criteria were as follows: an adequate performance status (0 -2), renal function (creatinine , 1.5 mg/dl) and hepatic reserve capacity (total bilirubin , 3.0 mg/dl). This study was performed according to the guidelines of the Helsinki Declaration, and the study protocol was approved by the ethics committee at our institution. Written informed consent was obtained from all the patients and/or a relative.
PATIENTS AND METHODS

PATIENTS
The diagnosis of HCC was made histopathologically (n ¼ 3) or clinically based on imaging studies such as contrastenhanced multidetector-row computed tomography (CT) and/or magnetic resonance imaging (n ¼ 21). The serum alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) levels were also evaluated. PVTT was diagnosed using contrast-enhanced CT (appearance of an intraluminal mass), a post-arterial portogram via the superior mesenteric artery (appearance of filling defects in the portal vein) and/ or using hepatic angiography [appearance of 'threads and streaks ' (26) ]. Table 1 shows the characteristics of the patients. The etiology of the HCC was associated with infection with hepatitis B virus in 1 patient, infection with hepatitis C virus in 16 patients, infections with hepatitis B and C viruses in 2 patients and alcohol-abuse in 5 patients. According to the Child -Pugh classification, 19 patients were Grade A and Prothrombin activity ratio (%) 100/.100 13/11
Albumin (g/dl) ,3.5/3.5 12/12 AFP (ng/ml) 0 -100/100-1000/1000-10 000/10 000-8/5/3/8 DCP (mAU/ml) 0 -100/100-1000/1000-10 000/10 000-10/4/4/6
Ascites (yes/no) 8/16
PVTT location
Third-order branch 1
Second-order branch 4
First-order branch 8
Main portal trunk 11 70 HAI using cisplatin powder for HCC with PVTT 5 patients were Grade B. The serum alanine aminotransferase (ALT), total bilirubin, prothrombin activity ratio and albumin values were 18 -147 U/l (mean, 61 U/l), 0.3 -2.0 mg/dl (mean, 0.9 mg/dl), 75 -137% (mean, 101%) and 2.6 -4.4 g/dl (mean, 3.6 g/dl), respectively. The serum AFP and DCP values before the initial HAI treatment with cisplatin powder were 20 -207 890 ng/ml (mean, 27 885 ng/ml) and 16 -57 500 mAU/ml (mean, 9839 mAU/ml), respectively. The location of the tumor thrombosis was in the main portal trunk in 11 patients (45.8%), in a first-order branch in 8 patients (33.3%), in a second-order branch in 4 patients (16.7%) and in a third order branch in 1 patient (4.2%).
FINE POWDER FORMULATION OF CISPLATIN (CISPLATIN POWDER)
Cisplatin powder is a fine powder formulation (IA call w ; cisplatin, 100 mg vial) and is easily dissolved in physiological saline suitable for the preparation of high-concentration aqueous solutions (1.4 mg/ml). One hundred milligrams of cisplatin powder are dissolved in 70 ml of saline heated to 508C, and the resulting solution is administered intra-arterially as a dose of 65 mg/m 2 over a period of about 30 min using a mechanical infusion pump.
HAI PROCEDURE
The Seldinger technique was used to gain access to the right femoral artery. A 5 Fr shepherd hook catheter (Clinical Supply Co., Gifu, Japan) was advanced into the celiac artery, and a 2 Fr microcatheter (Clinical Supply Co.) was then advanced through the first catheter into the proper hepatic artery, where it was used to intra-arterially infuse the cisplatin powder solution. To prevent cisplatin-induced renal damage, 3000 ml of infusion solution was infused intravenously during the first day of HAI therapy, and 1500 ml per day was infused on each of the next 3 days. The treatment was repeated at an interval of 4 -6 weeks if an adequate performance status, renal function and hepatic reserve capacity were maintained.
CLINICAL RESPONSE AND TOXICITY EVALUATION
To evaluate the efficacy of HAI therapy with cisplatin powder, measurable tumor lesions and the PVTT were assessed using CT at 4 weeks after each HAI treatment. Tumor response was evaluated according to the Response Evaluation Criteria for Solid Tumors (RECIST) (27) , and the serum AFP and DCP levels before and 4 weeks after each treatment. The observed toxicity was assessed according to the Common Terminology Criteria for Adverse Effects (CTCAE version 3.0).
STATISTICAL ANALYSIS
The endpoint of this study was the survival period of HCC patients with PVTT after the start of the first HAI treatment with cisplatin powder. The Kaplan -Meier method was used to plot the estimated survival curves. To identify positive prognostic factors in HCC patients with PVTT, 14 pre-and post-treatment variables were assessed using univariate analyses ( Table 2 ). The statistical significance of the difference in survival between the two groups was evaluated using the log-rank test. All the data analyses were performed using a statistical software package (SPSS version 17.0; SPSS Inc., Chicago, IL, USA).
RESULTS
The patients underwent a total of 57 sessions of HAI treatments, and the average number of sessions per patient was 2.4 (range, 1 -6 sessions). The number of HAI sessions was A complete response (CR) and a partial response (PR) were achieved in one and four patients, respectively, after three to five sessions of HAI treatments, and the objective response (OR) rate was 20.8%. Stable disease (SD) was achieved in one patient (4.2%) after three HAI sessions. Progressive disease (PD) was observed in 18 patients (75%). The survival rate calculated from the start of HAI with cisplatin powder was 38% at 1 year and 16% at 2 years (Fig. 1A) , and the median survival time was 7.0 months. Univariate analyses identified three significant prognostic factors related to survival: therapeutic effect (CR and PR vs. SD and PD, P , 0.01), age (P ¼ 0.017) and serum ALT level (P ¼ 0.016). The median survival times for responders (CR þ PR) and non-responders (SD þ PD) were 37.3 and 5.6 months, respectively; these values were significantly different (P , 0.01). The serum AFP and DCP levels after HAI therapies with cisplatin powder were increased in 18 PD patients and decreased in 1 patient with a CR, 4 patients with a PR and 1 patient with an SD. At the end of the study, 14 patients (58.3%) had died of liver failure, 3 (12.5%) of gastrointestinal bleeding and 1 (4.2%) of HCC rupture. Figures 2 and 3 show representative CR and PR cases. Figure 2 shows a case in which the right first branch of the portal vein was obstructed by PVTT before the start of HAI therapy ( Fig. 2A) , but the thrombosis disappeared and the vessel recanalized after five sessions of HAI therapy with cisplatin powder (Fig. 2B) . The serum AFP and DCP levels decreased from 548 to 61 ng/ml and from 16 to 11 mAU/ml, respectively. This patient survived for 44 months between the start of HAI therapy and the endpoint of the study. Figure 3 shows a case in which the right first branch of the portal vein was dilated and filled with PVTT before HAI therapy (Fig. 3A) , but the thrombosis disappeared and the vessel recanalized after 3 sessions of HAI therapy with cisplatin powder (Fig. 3B) . The serum AFP and the DCP levels decreased from 24830 to 39 ng/ml and from 59 to 13 mAU/ ml, respectively. This patient survived for 20 months after the first session and eventually died of gastrointestinal bleeding.
The toxicities of the HAI treatments with cisplatin powder are summarized in Table 3 . HAI therapy was not discontinued because of a deterioration in the liver or renal function in any of the patients. The non-hematological toxicities consisted mainly of anorexia, nausea and fatigue; however, Grade 3 or 4 non-hematological toxicities were limited to an elevated bilirubin level, AST level and/or ALT level and/or reduced albumin level in 11 sessions (19.3%), and hematological toxicities were limited to thrombocytopenia in 4 sessions (7.0%). All the manifestations of toxicity returned to their basal levels within 2 weeks after treatment.
DISCUSSION
Cisplatin has been used for the treatment of HCC; however, the efficacy of systemic chemotherapy with cisplatin alone has been limited (28) . The median survival time of HCC patients with PVTT receiving systemic chemotherapy has been reported to be 3.9 months (12). In addition, the effect of HAI therapy using cisplatin remains controversial. Kajanti et al. (24) showed high OR (40%) and SD (50%) rates when 
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HAI using cisplatin powder for HCC with PVTT cisplatin was administered at a total dose of 50 mg/m 2 and at a concentration of 0.16 mg/ml for 1.5 h in 10 HCC patients. However, Chung et al. (16) reported an unfavorable response rate (14%) and median survival time (77 days) when cisplatin was administered at a total dose of 2 mg/kg and a conventional concentration of 0.5 mg/ml for 15 min in 23 HCC patients with PVTT and/or extrahepatic metastasis. Cisplatin activity is concentration-and time-dependent (29); the firstpass uptake by liver tumors has been reported to be 48.4% of the cisplatin administered intra-arterially (30) . Therefore, the cisplatin taken up in PVTT during conventional cisplatin therapy, even if the cisplatin is administered during HAI chemotherapy, might not be sufficient to exert an antitumor effect against HCC with vascular invasion.
Cisplatin powder (IA call w ) was approved for use in HAI chemotherapy for the treatment of HCC in Japan without the use of lipiodol or embolic material. Cisplatin powder is readily soluble and is more suitable for the preparation of high-concentration aqueous solutions (1.4 mg/ml) than conventional cisplatin formulations (0.5 mg/ml). Therefore, a single session of HAI therapy with cisplatin powder has the benefit of increasing the local drug concentration in the HCC and is expected to have a high therapeutic efficacy. Using this regimen, Yoshikawa et al. (25) recently reported a favorable response rate (33.8%) and 1-and 2-year survival rate (67.5% and 50.8%, respectively) in 80 advanced HCC patients; however, the therapeutic efficacy of this regimen in HCC patients with PVTT has not been fully clarified. In the present study, the overall median survival time and objective response rate were 7.0 months and 20.8%, respectively, both of which were apparently superior than those reported by Chung et al. (16), who reported the intra-arterial administration of conventional single-agent cisplatin.
Since cisplatin reportedly amplifies the antitumor effect of 5-FU, HAI therapy using a combination of cisplatin and 5-FU is a widely used regimen for patients with unresectable HCC (14, 17, 31) . Using this combined regimen, Ando et al. (14) and Itamoto et al. (31) reported a favorable response rate of 44% and 33%, and a median survival time of 10.2 and 7.5 months, respectively, among HCC patients with PVTT (Table 4) . These results may indicate that combination therapy consisting of cisplatin and 5-FU is more effective than HAI therapy with cisplatin alone. However, the combination therapy of cisplatin and 5-FU requires the implantation of an injection port and a relatively long-term treatment period, at least 1 month. To prevent the occlusion of the implanted port and catheter, a heparin solution needs to be infused once or twice a week via the injection port. A single session of HAI therapy with cisplatin powder alone does not require the implantation of a reservoir, and scheduled hospitalization is limited to about 1 week, since one treatment consists of only one infusion. This treatment regimen might decrease the burden of hospitalization and improve the patients' quality of life.
The current standard therapeutic regimen for the management of HCC with PVTT is an orally active multikinase inhibitor, sorafenib (10, 32) . The median survival time of patients with advanced HCC treated with sorafenib was 3 months longer than that of patients receiving a placebo (33) , and sorafenib has also been shown to provide a clinical benefit in subgroup analyses of patients with macroscopic vascular invasion (33, 34) . However, the rates of treatment discontinuation because of drug-induced adverse events in the sorafenib treatment group were 14.8 -29%, and only Child -Pugh class A patients were eligible for treatment (33, 34) . In the present study, HAI treatment with cisplatin powder was not discontinued because of adverse events in any of the patients, who were all classified as Child -Pugh class A or B. Furthermore, combination therapy consisting of systemic interferon-a and intra-arterial 5-FU infusion has been widely used for the treatment of HCC patients with PVTT in Japan (35, 36) . Obi et al. (36) reported a median survival time of 6.9 months and 1-and 2-year survival rates of 34% and 18%, respectively; these results were also comparable with those of the present study. Further study involving a larger number of patients is needed to determine whether HAI therapy with cisplatin powder is clinically beneficial, compared with other chemotherapeutic regimens.
The present study had some limitations, as follows: (i) this study was conducted in a retrospective manner and (ii) the sample size was too small for the analysis of prognostic factors. When we started this study, sorafenib, the current standard therapeutic regimen for the treatment of HCC with PVTT, had not yet been approved by the Ministry of Health, Labour, and Welfare of Japan. In the single institutional setting of our study, the number of candidates for this HAI chemotherapy was not large enough to conduct a randomized control trial. Although further large-scale clinical trials are needed to determine whether a HAI therapy with cisplatin powder may help to prolong the life span of treated patients, our results clearly show that this regimen should be adopted as a treatment of choice for HCC patients with PVTT.
In conclusion, HAI therapy with cisplatin powder can be considered as an optional palliative therapy for HCC patients with PVTT who have a good hepatic reserve. MST, median survival time; OR, objective response; OS, overall survival was followed by 1 year after treatment initiation.
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